NURS FPX 4025 Assessment 4 Presenting Your PICO(T) Process Findings to Your Professional Peers

NURS FPX 4025 Assessment 4 Presenting Your PICO(T) Process Findings to Your Professional Peers

Name

Capella university

NURS-FPX4025 Research and Evidence-Based Decision Making

Prof. Name

Date

 Presenting Your PICO(T) Process Findings to Your Professional Peers

The progressive respiratory disorder COPD produces airway blockages together with impaired lung capabilities and recurrent episodes, which reduce patient wellness and raise healthcare requirements. Smoking stands as the main disease risk factor, yet stopping smoking provides the best way to minimize disease advancement and enhance patient outcomes. Even though developing nicotine addiction and emotional barriers have proven to be major obstacles to successful quitting (Jo, 2022). The assessment determines which treatment approach, using Long-Acting beta agonist (LBA) exclusively or combining LABA with LAMA and ICS, provides the most effective exacerbation reduction during a three-month period.

Diagnosis: Prognosis, Potential Risks, and Associated Complications

The respiratory condition known as COPD advances through stages which causes persistent airflow blockage that produces breathing difficulties together with decreased lung capacity. Chronic obstructive pulmonary disease develops when people breathe in respiratory irritants over many years, and smoking cigarettes stands as the main trigger for this development. COPD holds the position of the world’s fourth most fatal disease and caused 3.5 million deaths in 2021, which equated to 5% of global deaths. A deterioration in lung function causes activities to become more challenging, which substantially reduces patient life quality (WHO, 2024).

The progression of COPD varies depending on disease severity and treatment effectiveness. Without appropriate intervention, patients face worsening lung function, increased hospitalizations due to exacerbations, and poorer overall health outcomes. COPD is associated with comorbidities, including cardiovascular disease, osteoporosis, muscle wasting, and depression.

The disease becomes severe in patients with inadequate access to healthcare, poor disease control, and continued smoking habits. In advanced stages, COPD can lead to respiratory failure, necessitating long-term oxygen therapy or mechanical ventilation. Personalized, evidence-based treatment strategies are essential to managing COPD. Optimizing pharmacologic therapy, including LABA monotherapy or triple therapy (LABA/LAMA/ICS), helps reduce exacerbations (Miravitlles et al., 2022). A patient-centered approach improves disease outcomes while minimizing unnecessary exposure to medications.

Formulating the Research Question Using the PICO(T) Framework

A research question was formulated using the PICO (T) framework to determine the most effective pharmacological intervention for managing moderate to severe COPD. The question is: In adult patients diagnosed with moderate to severe COPD (P), how does LABA therapy alone (I) compared to triple therapy with LABA, Long-Acting Muscarinic Antagonist (LAMA), and Inhaled Corticosteroids (ICS) (C) affect exacerbation frequency and symptom control (O) over three months (T)?

The population (P) consists of adults with moderate to severe COPD, as this stage requires maintenance therapy to prevent exacerbations and improve quality of life. The intervention (I) is LABA monotherapy, commonly prescribed for symptom management in stable COPD patients. The comparison (C) is triple therapy (LABA/LAMA/ICS), which is often recommended for patients with frequent exacerbations or high inflammation markers (Miravitlles et al., 2022).

The outcome (O) is measured by reducing exacerbation frequency and improving symptom control. The timeframe (T) is three months, providing a clinically relevant period to assess treatment response. This structured research question facilitates an evidence-based comparison of COPD treatment strategies to optimize patient care.

Summary of Evidence from Peer-Reviewed Sources

A comprehensive literature review was conducted using PubMed, CINAHL, and the Cochrane Library to evaluate the effectiveness of LABA monotherapy versus triple therapy (LABA/LAMA/ICS) in managing moderate to severe COPD. Studies were selected based on relevance to COPD management and credibility using the CRAAP (Currency, Relevance, Authority, Accuracy, and Purpose) criteria. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines (2023) recommend triple therapy for patients experiencing frequent exacerbations despite initial bronchodilator use.

However, for stable patients with lower exacerbation risk, LABA monotherapy is considered sufficient. A systematic review by Fukuda et al. (2023) found that triple therapy significantly reduced exacerbations in COPD patients but showed no additional benefit over LABA therapy in controlling symptoms for those without frequent exacerbations. Similarly, a study by Davidescu et al. (2023) highlighted that ICS withdrawal in patients with eosinophil counts below 300 cells/mm³ did not lead to an increased exacerbation rate, supporting the idea that LABA monotherapy remains effective in specific patient populations.

Another systematic review by Zhang et al. (2024) further confirmed that while triple therapy provides superior exacerbation control, LABA monotherapy is sufficient for stable patients without a history of frequent exacerbations. These findings reinforce the need for personalized COPD treatment strategies, ensuring patients receive appropriate therapy based on their exacerbation risk and inflammatory profile.

Evidence-Based Response to the PICO(T) Question

The findings of research sourced from peer-reviewed literature prove that COPD treatments must be tailored specifically for patients by taking their individual factors, including exacerbation background and inflammatory indicator performance, into account. The 2023 GOLD guidelines advise health providers to administer triple therapy (LABA/LAMA/ICS) to patients who experience regular exacerbations but indicate LABA monotherapy works for those showing stable disease symptoms. The study conducted by Fukuda et al. (2023) showed LABA monotherapy provides effective results for patients who have eosinophil counts less than 300 cells/mm³ and no history of severe exacerbations.

Single bronchodilator monotherapy proved to be effective for stable COPD patients, according to the research by Davidescu et al. (2023). Zhang et al. (2024) agreed with these findings by stating that stable COPD patients with reduced inflammation markers require LABA monotherapy, although high-risk patients derive advantages from triple therapy. The research has shown that individualized treatments require consideration of both symptom control and prevention of exacerbations while aiming to reduce excess use of ICS medication.

Essential Care Steps Guided by Evidence-Based Recommendations

The reviewed evidence establishes guidelines that help healthcare providers create customized methods to improve COPD care. Treatment selection calls for complete patient assessments that measure exacerbation histories along with symptom severity evaluations and measurements of eosinophil numbers. The treatment of steady COPD patients who experience rare exacerbations should include LABA medications alone, yet triple therapy, including LABA/LAMA/ICS, provides the most effective symptom management for patients experiencing frequent exacerbations and elevated eosinophil counts.

The key dates for follow-up checks should be one month, three months, and six months. These provide opportunities to evaluate treatment results while tracking negative side effects and making therapy adjustments when necessary. The care process should provide each patient with individualized education about COPD evolution, proper medication use, and improper ICS safety concerns. Multiple healthcare providers consisting of pulmonologists, primary care providers, and respiratory therapists must work together to manage COPD comprehensively. The application of evidence-based practice models, especially the JHNEBP framework, creates structured interventions that lead to better long-term patient results (Olivo et al., 2022).

Conclusion

The effective management of moderate to severe COPD depends on individual patient factors which need personalized treatment strategies. The medication strategy of LABA monotherapy works best for stable patients, but triple therapy (LABA/LAMA/ICS) provides superior benefits for individuals experiencing many exacerbations. Optimal results require patients to receive consistent follow-up care along with educational sessions as well as coordinated treatment among health professionals. Strategies based on evidence prove effective at controlling symptoms while decreasing exacerbations and bettering patients’ quality of life by preventing medication risks that are unnecessary.

References

Davidescu, L., Andrei, D., Mekeres, F., Goman, A., Stefania, N., & Rajnoveanu, R. (2023). Phenotype of COPD: “Frequent exacerbator” and biomarkers use in clinical practice. Pharmacophore, 14(4), 40–49. https://doi.org/10.51847/yyzhyvtysb

Fukuda, N., Horita, N., Kaneko, A., Goto, A., Kaneko, T., Ota, E., & Kew, K. M. (2023). Long-Acting Muscarinic Antagonist (LAMA) plus Long-Acting Beta-Agonist (LABA) versus LABA plus Inhaled Corticosteroid (ICS) for stable chronic obstructive pulmonary disease. The Cochrane Library, 2023(6). https://doi.org/10.1002/14651858.cd012066.pub3

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). Global initiative for chronic obstructive lung disease – GOLD. https://goldcopd.org/

Jo, Y. S. (2022). Long-term outcome of chronic obstructive pulmonary disease: A review. Tuberculosis and Respiratory Diseases, 85(4), 289–301. https://doi.org/10.4046/trd.2022.0074

NURS FPX 4025 Assessment 4 Presenting Your PICO(T) Process Findings to Your Professional Peers

Miravitlles, M., Kawayama, T., & Dreher, M. (2022). LABA/LAMA as first-line therapy for COPD: A summary of the evidence and guideline recommendations. Journal of Clinical Medicine, 11(22), 6623. https://doi.org/10.3390/jcm11226623

Olivo, M. V., Halpin, D. M. G., Han, M. K., Hanania, N. A., Kalhan, R., Lipson, D. A., MacIntyre, N., Midwinter, D., Stiegler, M., Young, C., Martinez, F. J., & Criner, G. J. (2022). Best practice management of patients with chronic obstructive pulmonary disease: A case-based review. The Journal for Nurse Practitioners, 18(7), 730–735. https://doi.org/10.1016/j.nurpra.2022.03.010

World Health Organization (WHO). (2024, November 6). Chronic obstructive pulmonary disease (COPD). https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

Zhang, S., Wang, J., Li, X., & Zhang, H. (2024). Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: An overview of systematic reviews. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241259634